Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

StatusUnknown
PhasePhase 2/3
Started

Record status This record was last updated February 14, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Site contacts updated at 1 of 3 sitesv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 30, 2024 to Sep 2, 2024
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).
Trial Details
NCT Number NCT06477536
Lead Sponsor Shanghai Huaota Biopharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Generalized Pustular Psoriasis
Related terms Psoriasis
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov